← Eichor
Condition: Recurrent Head And Neck Squamous Cell Carcinoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Recurrent Head And Neck Squamous Cell Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After Radio
Phase 1 · 1 location(s) · West China Hospital · NCT07545967A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizuma
Phase 2/Phase 3 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT07554456A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Ca
Phase 3 · 205 location(s) · Merus B.V. · NCT06525220A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell C
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06006169Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aerodigestive
NA · 3 location(s) · Fondation Hôpital Saint-Joseph · NCT06061705Establishment of a Microfluidic Based Liquid Biopsy Platform for Recurrent/Metastatic Head and Neck Cancers Prognosticat
Phase N/A · 1 location(s) · National Taiwan University Hospital · NCT06678724BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity and HPV-negative Oropharyngeal Squ
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06448026A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma
Phase 1/Phase 2 · 1 location(s) · West China Hospital · NCT06753747A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard
Phase 2 · 1 location(s) · Shanghai Henlius Biotech · NCT06769113Efficacy and Safety of Paclitaxel Polymeric Micelles in Patients With Recurrent/Metastatic Head and Neck Squamous Cell C
Phase 2 · 1 location(s) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao · NCT07662746A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC
Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06597565Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and
Phase N/A · 1 location(s) · University of Rome Tor Vergata · NCT07448727Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN
Phase 2 · 2 location(s) · Eye & ENT Hospital of Fudan University · NCT05260671A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Meta
Phase 2 · 25 location(s) · Regeneron Pharmaceuticals · NCT06769698Predicting Early Tumor Recurrence in Patients With Esophageal Squamous Cell Carcinoma
Phase N/A · 2 location(s) · City of Hope Medical Center · NCT06476067A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor
Phase 1/Phase 2 · 10 location(s) · A2 Biotherapeutics Inc. · NCT06682793Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors
Phase 1 · 1 location(s) · Therorna · NCT07081984Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Pos
Phase 2 · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT06885814Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for R
Phase 2 · 8 location(s) · Gruppo Oncologico del Nord-Ovest · NCT06869473A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metas
Phase 1/Phase 2 · 3 location(s) · Taipei Veterans General Hospital, Taiwan · NCT07136545Iparomlimab and Tuvonralimab in HNSCC
Phase 2 · 1 location(s) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao · NCT07090317Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Phase 1 · 30 location(s) · Calico Life Sciences LLC · NCT04777994Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell
Phase 2 · 1 location(s) · Groupe Oncologie Radiotherapie Tete et Cou · NCT06640725Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma
Phase 1/Phase 2 · 17 location(s) · Nykode Therapeutics ASA · NCT06016920Oropharynx (OPX) Biomarker Trial
Phase N/A · 1 location(s) · Mayo Clinic · NCT06356272Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
Phase 2 · 100 location(s) · National Cancer Institute (NCI) · NCT07195734Surufatinib Combined with Envolizumab As Second-line Treatment for Recurrent/Metastatic HNSCC
Phase 2 · 1 location(s) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao · NCT06876844Becotatug Vedotin Combined With Pucotenlimab for Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma
Phase 2 · 1 location(s) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao · NCT07632339A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurre
Phase 3 · 196 location(s) · Janssen Research & Development, LLC · NCT07276399
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.